Lisata's Marea deal expands cardioendocrine pipeline with $225M financing
Lisata Therapeutics has acquired Marea Therapeutics and raised $225 million in a private placement, expanding its cardioendocrine portfolio. The funds will advance MAR001/005 and MAR002 through key milestones, with topline data targeted for 2027. Dilution to existing holders and aggressive cost-cutting accompany the deal, while a Kuva Labs merger-breach lawsuit adds near-term legal uncertainty.
View signal analysis